Personalized Oncolytic Virus Combinations: Current Evidence and Clinical Implications

Abstract

Personalized oncolytic virus (OV) combinations represent a promising frontier in cancer therapy by harnessing the selective tumor-lysing properties of engineered viruses and tailoring treatment to individual tumor profiles. This review synthesizes recent clinical and experimental evidence on the integration of OVs with other therapeutics, emphasizing mechanisms, clinical outcomes, and practical application in oncology. Advances in molecular profiling and immunotherapy have enabled more precise patient stratification and combination strategies, potentially improving response rates and durability. Key challenges include optimizing patient selection, managing safety, and integrating personalized OVs into standard clinical pathways. We conclude with expert insights on future research directions and the evolving role of personalized OV combinations in cancer care.

Introduction

Oncolytic virotherapy has emerged as a novel modality in the armamentarium against cancer, leveraging viruses that selectively infect, replicate within, and destroy malignant cells while sparing normal tissues. While single-agent OV therapies have demonstrated efficacy in select tumor types, a growing body of evidence supports the rational design of personalized OV-based combination regimens. These strategies aim to enhance antitumor immune responses, overcome resistance, and exploit tumor heterogeneity. The convergence of next-generation sequencing, immuno-oncology, and synthetic biology has propelled the development of individualized approaches that match viral agents and adjunctive therapies to the patient's unique tumor biology. This review examines the current landscape, mechanisms, and clinical relevance of personalized OV combinations, with a focus on translating recent scientific advances into practice.

Epidemiology / Disease Burden

The global burden of cancer continues to escalate, with over 19 million new cases and nearly 10 million deaths reported annually. Many solid tumors, particularly those refractory to conventional treatments, remain significant contributors to morbidity and mortality. Despite advances in targeted therapies and immunotherapies, a substantial proportion of patients experience relapse or progression, underscoring the need for innovative strategies such as personalized OV combinations. Epidemiological studies indicate that patients with advanced melanoma, glioblastoma, and certain refractory solid tumors could benefit most from these interventions, given their poor prognosis and limited therapeutic options.

Pathophysiology

Oncolytic viruses exploit unique vulnerabilities of cancer cells, including defective antiviral responses, altered cell surface receptors, and permissive intracellular environments. Engineered OVs can be further modified to express immune-stimulatory molecules or prodrug-converting enzymes, thereby enhancing both direct cytolysis and immune-mediated tumor clearance. Personalization is achieved by aligning viral tropism, genetic payloads, and combination partners (e.g., checkpoint inhibitors, targeted therapies) with tumor-specific molecular signatures, immune milieu, and resistance mechanisms. Tumor heterogeneity, immune evasion, and the tumor microenvironment (TME) play critical roles in response variability, justifying the need for individualized approaches.

Risk Factors

Selection for personalized OV therapy necessitates careful consideration of patient- and tumor-specific risk factors. Tumor characteristics such as low immunogenicity, high mutational burden, and immune checkpoint expression can influence OV sensitivity. Host factors, including prior immunosuppression, antiviral immunity, and comorbidities, may impact safety and efficacy. Molecular profiling to identify actionable mutations, viral entry receptors, and immune signatures is increasingly incorporated into risk stratification algorithms. Moreover, patients with heavily pretreated, refractory malignancies or limited therapeutic alternatives are often prioritized for OV-based clinical trials.

Clinical Features

Patients eligible for personalized OV combinations typically present with advanced or metastatic disease, often after standard therapies have failed. Clinical features vary by tumor type but may include rapidly progressive lesions, symptomatic tumor burden, or immune-excluded phenotypes. The selection of OVs and adjunctive agents is informed by tumor histology, molecular markers, and the patient's immune competence. Real-world evidence highlights the importance of baseline performance status, organ function, and prior treatment history in guiding therapy selection and monitoring for adverse events.

Diagnosis

Establishing eligibility for personalized OV regimens involves a multimodal diagnostic approach. Histopathological confirmation, molecular profiling (e.g., next-generation sequencing), and immune landscape characterization are essential. Biomarkers such as PD-L1 expression, tumor mutational burden, and viral entry receptor profiling (e.g., CD46, Nectin-1) enable rational pairing of OVs with targeted immunotherapies. Advanced imaging techniques, liquid biopsy, and spatial transcriptomics are increasingly used to monitor treatment response and detect minimal residual disease, supporting timely therapy modifications.

Treatment & Management

Personalized OV combinations are administered in specialized oncology centers, often within the context of clinical trials. Treatment paradigms may include intratumoral or systemic OV delivery, combined with checkpoint inhibitors (e.g., anti-PD-1/PD-L1), targeted therapies (e.g., kinase inhibitors), or conventional modalities (chemotherapy, radiotherapy). Dosing regimens are tailored based on tumor burden, immune status, and viral pharmacokinetics. Multidisciplinary management is crucial, with close monitoring for immune-related adverse events, viral shedding, and treatment-emergent toxicities. Patient education, supportive care, and longitudinal follow-up optimize outcomes and safety.

Recent Advances / Emerging Therapies

Recent clinical trials have demonstrated the efficacy of personalized OV combinations, particularly in melanoma, glioblastoma, and head and neck cancers. For example, talimogene laherparepvec (T-VEC) in combination with immune checkpoint inhibitors has shown durable responses in advanced melanoma, with ongoing studies exploring biomarkers of response and resistance. Novel OVs engineered to express cytokines (e.g., GM-CSF, IL-12), bispecific T-cell engagers, or tumor-associated antigens are under investigation. Advances in synthetic biology enable the rapid customization of OV genomes, enhancing tumor selectivity and immunogenicity. Early-phase studies suggest synergistic effects when OVs are combined with adoptive cell therapies, epigenetic modulators, or oncolytic peptides. The integration of artificial intelligence and omics data is poised to further refine patient selection and therapy design.

Guideline Recommendations

Professional guidelines recognize the investigational status of most personalized OV combinations, recommending their use within clinical trials or compassionate use protocols. The National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) highlight the importance of molecular profiling, multidisciplinary evaluation, and robust informed consent. Participation in registries and real-world data collection is encouraged to inform future guideline updates. Personalized OV regimens should be considered for patients with refractory or relapsed malignancies, particularly when supported by molecular or immunological rationale and institutional expertise.

Conclusion

Personalized oncolytic virus combinations represent a paradigm shift in cancer therapy, offering tailored, mechanism-driven interventions for patients with limited options. The convergence of molecular diagnostics, immuno-oncology, and synthetic virology enables precise patient stratification and rational combination strategies. While challenges remain in optimizing safety, efficacy, and clinical integration, accumulating evidence supports the promise of personalized OV regimens in improving cancer outcomes. Continued research, collaborative trials, and guideline development will be key to fully realizing the potential of this innovative approach in oncology practice.